Citations

Mayo Clinic

Showing 10 of 108551 citations.

Fourier Analysis of the Vertical Ground Reaction Force During Walking: Applications for Quantifying Differences in Gait Strategies
Trentadue, Taylor P. , Schmitt, Daniel , Trentadue, Taylor P

Journal of Applied Biomechanics | April 12, 2024 | Volume: 40 | Issue: 3 | Pages: 250-258

10.1123/jab.2023-0151 | PMID 38608710 Get It

Time series biomechanical data inform our understanding of normal gait mechanics and pathomechanics. This study examines the utility of different quantitative methods to distinguish vertical ground reaction forces (VGRFs) from experimentally distinct gait strategies. The goals of this study are to compare measures of VGRF data—using the shape factor method and a Fourier series-based analysis—to (1) describe how these methods reflect and distinguish gait patterns and (2) determine which Fourier series coefficients discriminate normal walking, with a relatively stiff-legged gait, from compliant walking, using deep knee flexion and limited vertical oscillation. This study includes a reanalysis of previously presented VGRF data. We applied the shape factor method and fit 3- to 8-term Fourier series to zero-padded VGRF data. We compared VGRF renderings using Euclidean L 2 distances and correlations stratified by gait strategy. Euclidean L 2 distances improved with additional harmonics, with limited improvement after the seventh term. Euclidean L 2 distances were greater in shape factor versus Fourier series renderings. In the 8 harmonic model, amplitudes of 9 Fourier coefficients—which contribute to VGRF features including peak and local minimum amplitudes and limb loading rates—were different between normal and compliant walking. The results suggest that Fourier series-based methods distinguish between gait strategies.
From the Editor-in-Chief's Desk: Advances in Patient-Centered Treatment for Attention-Deficit/Hyperactivity Disorder
Croarkin, Paul E.

Journal of Child and Adolescent Psychopharmacology | April 12, 2024 | Volume: 34 | Issue: 3 | Pages: 117-118

10.1089/cap.2024.29257.editorial | PMID 38608009 Get It

Impact of age over 70 years in the new allocation system on the outcomes of heart transplantation in the US
Gemelli, Marco , Doulamis, Ilias P. , Addonizio, Mariangela, Tzani, Aspasia , Rempakos, Athanasios, Dunque, Ernesto Ruiz, Kampaktsis, Polydoros Ν. , Guariento, Alvise , Asleh, Rabea , Álvarez, Paulino , Briasoulis, Αlexandros

Clinical Transplantation | April 12, 2024 | Volume: 38 | Issue: 4 | Pages: No page available

10.1111/ctr.15317 | PMID 38607287 Get It

AbstractBackgroundUnited Network for Organ Sharing (UNOS) allocation criteria changed in 2018 to accommodate the increased prevalence of patients on a ventricular assist device as a bridge to heart transplant and prioritize sicker people in anticipation of a heart graft. We aimed to assess the impact of patient age in the new allocation policy on mortality following heart transplantation. Secondary outcomes included the effect of age ≥70 on post‐transplant events, including stroke, dialysis, pacemaker, and rejection requiring treatment.MethodsThe UNOS Registry was queried to identify patients who underwent heart transplants alone in the US between 2000 and 2021. Patients were divided into groups according to their age (over 70 and under 70 years old).ResultsPatients aged over 70 were more likely to require dialysis during follow‐up, but less likely to experience rejection requiring treatment, compared with patients aged <70. Age ≥70 in the new allocation system was a significant predictor of 1‐year mortality (adjusted HR: 1.41; 95% CI: 1.05–1.91; p = .024), but its effect on 5‐year mortality was not significant after adjusting for potential confounders (adjusted HR: 1.27; 95% CI:.97–1.66; p = .077). Undergoing transplantation under the new allocation policy vs the old allocation policy was not a significant predictor of mortality in patients over 70 years old.ConclusionsAge ≥70 is a significant predictor of 1‐year mortality following heart transplantation, but not at 5 and 10 years; however, the new allocation does not seem to have changed the outcomes for this group of patients.
An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study
Dunn, Winston , Li, Yanming , Singal, Ashwani K. , Díaz, Luis Antonio , Idalsoaga, Francisco , Ayares, Gustavo , Arnold, Jorge , Ayala-Valverde, María , Pérez, Diego , Gomez, Jaime, Escarate, Rodrigo , Ramírez, Carolina , Morales‐Arráez, Dalia , Qian, Steve , Ahn, Joseph , Buryska, Seth , Mehta, Heer , Dunn, Nicholas , Bumbu, Andreea , Horhat, Adelina , Attar, Bashar, Agrawal, Rohit , Echavaría, Victor , Cuyàs, Berta , Poca, María , Maiwall, Rakhi , Rao, Padaki Nagaraja , Guerra-Salazar, Patricia, Kubánek, Natália , Prado, Verónica , Clemente, Ana , Haider, Tehseen, Chacko, Kristina R. , Romero, Gustavo , Pollarsky, Florencia , Toro, Luis, Yaquich, Pamela, Garrido, María Laura , Dirchwolf, Melisa , Vargas, Vı́ctor , Jiménez, César , García–Tsao, Guadalupe , Ortiz, Guillermo, Kamath, Patrick S. , Shah, Vijay H. , Díaz, Luis A , Idalsoaga, Francisco , Ayares, Gustavo , Arnold, Jorge , Ayala-Valverde, María , Perez, Diego , Ramirez-Cadiz, Carolina , Mehta, Heer , Dunn, Nicholas , Horhat, Adelina , Agrawal, Rohit , Poca, Maria , Soriano, German , Jalal, Prasun K , Kulkarni, Anand V , Skladaný, Lubomir , Pollarsky, Florencia D , Restrepo, Juan C , Mendizabal, Manuel , Marciano, Sebastián , Dirchwolf, Melisa , Vargas, Victor , Jiménez, César , Arrese, Marco , Bataller, Ramon A , Ahn, Joseph C , Singal, Ashwani K , Cuyas, Berta , Dunn, Winston , Simonetto, Douglas A. , Fuentes–López, Eduardo , Zhang, Wei , Waleed, Muhammad Hasnain , Ştefănescu, Horia , Cabezas, Joaquín , Sarin, Shiv Kumar , Jalal, Prasun K. , Tijera, Fatima Higuera‐de la , Kulkarni, Anand V. , Rincón, Diego , Hudson, David, Ortiz, Guillermo, Abraldeṣ, Juan G. , Arrese, Marco , Arab, Juan Pablo

Hepatology | April 12, 2024 | Volume: 80 | Issue: 5 | Pages: 1196-1211

10.1097/hep.0000000000000883 | PMID 38607809 Get It

Background and Aims: Alcohol-associated hepatitis (AH) poses significant short-term mortality. Existing prognostic models lack precision for 90-day mortality. Utilizing artificial intelligence in a global cohort, we sought to derive and validate an enhanced prognostic model. Approach and Results: The Global AlcHep initiative, a retrospective study across 23 centers in 12 countries, enrolled patients with AH per National Institute for Alcohol Abuse and Alcoholism criteria. Centers were partitioned into derivation (11 centers, 860 patients) and validation cohorts (12 centers, 859 patients). Focusing on 30 and 90-day postadmission mortality, 3 artificial intelligence algorithms (Random Forest, Gradient Boosting Machines, and eXtreme Gradient Boosting) informed an ensemble model, subsequently refined through Bayesian updating, integrating the derivation cohort’s average 90-day mortality with each center’s approximate mortality rate to produce posttest probabilities. The ALCoholic Hepatitis Artificial INtelligence Ensemble score integrated age, gender, cirrhosis, and 9 laboratory values, with center-specific mortality rates. Mortality was 18.7% (30 d) and 27.9% (90 d) in the derivation cohort versus 21.7% and 32.5% in the validation cohort. Validation cohort 30 and 90-day AUCs were 0.811 (0.779–0.844) and 0.799 (0.769–0.830), significantly surpassing legacy models like Maddrey’s Discriminant Function, Model for End-Stage Liver Disease variations, age-serum bilirubin-international normalized ratio-serum Creatinine score, Glasgow, and modified Glasgow Scores (p < 0.001). ALCoholic Hepatitis Artificial INtelligence Ensemble score also showcased superior calibration against MELD and its variants. Steroid use improved 30-day survival for those with an ALCoholic Hepatitis Artificial INtelligence Ensemble score > 0.20 in both derivation and validation cohorts. Conclusions: Harnessing artificial intelligence within a global consortium, we pioneered a scoring system excelling over traditional models for 30 and 90-day AH mortality predictions. Beneficial for clinical trials, steroid therapy, and transplant indications, it’s accessible at: https://aihepatology.shinyapps.io/ALCHAIN/.
A 3‐step method for preparing cryopreserved samples of apheresis products for post‐thaw analysis yields a higher percentage of viable cells
Strasburg, Dustin J. , Sterner, Rosalie M. , Va, Sildane, Jacob, Eapen K., DiGuardo, Margaret , DiGuardo, Margaret A

Transfusion | April 12, 2024 | Volume: 64 | Issue: 5 | Pages: 866-870

10.1111/trf.17822 | PMID 38606842 Get It

AbstractBackgroundStandard flow cytometry protocols for CD34+ cell enumeration designed for fresh samples are not appropriate for cryopreserved products. Special protocols have been developed to remove the cryoprotectant by quickly washing a freshly thawed sample. Exposing cells to a large volume of hypotonic solution and subsequent washing process was hypothesized to cause lab‐induced cell death. Moreover, standard gating strategies must be altered to avoid reporting falsely high viabilities.Study Design and MethodsWe developed a novel method whereby thawed samples were diluted step‐wise to 1:2 by 3 additions of 1/3 sample volume using 1% Human Albumin in Dextran 40 (10% Low Molecular Weight Dextran in 0.9% NaCl) separated by 5 min between each addition. An additional 1:10 dilution was required to obtain a desired cell concentration for flow cytometry testing resulting in a 1:20 dilution.ResultsTwenty samples were tested simultaneously in a method comparison; the new method demonstrated significant increases in mean cell viabilities for white blood cells, hematopoietic progenitor cells, and T cells as well as reduced standard deviations for each parameter.DiscussionSlow, step‐wise dilutions of freshly thawed samples of cryopreserved apheresis products to 1:20 yielded higher and more precise viability measurements compared to quickly washing samples to remove DMSO.
The impact of the Affordable Care Act Medicaid Expansion in Medicare beneficiaries with peripheral artery disease
Henkin, Stanislav , Kearing, Stephen , Zacharias, Nikolaos , Creager, Mark A. , Young, Michael N. , Goodney, Philip P. , Columbo, Jesse A. , Creager, Mark A , Columbo, Jesse A , Henkin, Stanislav , Martínez‐Camblor, Pablo

Vascular Medicine | April 12, 2024 | Volume: 29 | Issue: 4 | Pages: 398-404

10.1177/1358863x241237776 | PMID 38607558 Get It

Background: In 2014, the Affordable Care Act Medicaid Expansion (ME) increased Medicaid eligibility for adults with an income level up to 138% of the federal poverty level. In this study, we examined the impact of ME on mortality and amputation in patients with peripheral artery disease (PAD). Methods: The 100% MedPAR and Part-B Carrier files from 2011 to 2018 were queried to identify all fee-for-service Medicare beneficiaries with PAD using International Classification of Diseases codes. Our primary exposure was whether a state had adopted the ME on January 1, 2014. Our primary outcomes were the change in all-cause 1-year mortality and leg amputation. We used a state-level difference-in-differences (DID) analysis to compare the rates of the primary outcomes among patients who were in states (including the District of Columbia) who adopted ME ( n = 25) versus those who were in states that did not ( n = 26). We performed a subanalysis stratifying by sex, race, region, and dual-eligibility status. Results: Over the 8-year period, we studied 37,743,929 patients. The average unadjusted 1-year mortality decreased from 2011 to 2018 in both non-ME (9.5% to 8.7%, p < 0.001) and ME (9.1% to 8.3%, p < 0.001) states. The average unadjusted 1-year amputation rate did not improve in either the non-ME (0.86% to 0.87%, p = 0.17) or ME (0.69% to 0.69%, p = 0.65) states. Across the entire cohort, the DID model revealed that ME did not lead to a significant change in mortality ( p = 0.15) or amputation ( p = 0.34). Conclusion: Medicaid Expansion was not associated with reduced mortality or leg amputation in Medicare beneficiaries with PAD.
Cardiovascular Disease Screening in Homeless Individuals: A Feasibility Study
Surey, Julian , Veitch, Martha, Al-Shakarchi, Nader , Burridge, Stan , Leonard, Mark, Munday, Sophie, Story, Alistair , Banerjee, Amitava , Al Shakarchi, Nader , Burridge, Stan , Story, Alistair , Banerjee, Amitava , Rogers, Sally J. , Leonard, Mark, Munday, Sophie

Journal of the American Heart Association | April 12, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/jaha.124.034413 | PMID 38606771 Get It

Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial
Babu, Suma , Nicholson, Katharine, Sampognaro, Paul J., Pant, Pravin, Spruill, Susan E. , Prudencio, Mercedes , Petrucelli, Leonard , Nix, Darrell, Landrette, Sean F., Nkrumah, Esther, Fandrick, Keith R. , Edwards, Joan, Prudencio, Mercedes , Rothstein, Jeffrey D. , Swenson, Andrea , Macklin, Eric A. , Paganoni, Sabrina , Gendron, Tania F. , Young, Peter R

Brain | April 12, 2024 | Volume: 147 | Issue: 9 | Pages: 2998-3008

10.1093/brain/awae109 | PMID 38606777 Get It

Abstract Apilimod dimesylate is a first-in-class phosphoinositide kinase, FYVE-type zinc finger-containing (PIKfyve) inhibitor with a favourable clinical safety profile and has demonstrated activity in preclinical C9orf72 and TDP-43 amyotrophic lateral sclerosis (ALS) models. In this ALS clinical trial, the safety, tolerability, CNS penetrance and modulation of pharmacodynamic target engagement biomarkers were evaluated. This phase 2a, randomized, double-blind, placebo-controlled, biomarker-end-point clinical trial was conducted in four US centres (ClinicalTrials.gov NCT05163886). Participants with C9orf72 repeat expansions were randomly assigned (2:1) to receive twice-daily oral treatment with 125 mg apilimod dimesylate capsules or matching placebo for 12 weeks, followed by a 12-week open-label extension. Safety was measured as the occurrence of treatment-emergent or serious adverse events attributable to the study drug and tolerability at trial completion or treatment over 12 weeks. Changes from baseline in plasma and CSF and concentrations of apilimod dimesylate and its active metabolites and of pharmacodynamic biomarkers of PIKfyve inhibition [soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB) upregulation] and disease-specific CNS target engagement [poly(GP)] were measured. Between 16 December 2021 and 7 July 2022, 15 eligible participants were enrolled. There were no drug-related serious adverse events reported in the trial. Fourteen (93%) participants completed the double-blind period with 99% dose compliance [n = 9 (90%) apilimod dimesylate; n = 5 (100%) placebo]. At Week 12, apilimod dimesylate was measurable in CSF at 1.63 ng/ml [standard deviation (SD): 0.937]. At Week 12, apilimod dimesylate increased plasma sGPNMB by &gt;2.5-fold (P &lt; 0.001), indicating PIKfyve inhibition, and lowered CSF poly(GP) protein levels by 73% (P &lt; 0.001), indicating CNS tissue-level proof of mechanism. Apilimod dimesylate met prespecified key safety and biomarker end-points in this phase 2a trial and demonstrated CNS penetrance and pharmacodynamic target engagement. Apilimod dimesylate was observed to result in the greatest reduction in CSF poly(GP) levels observed to date in C9orf72 clinical trials.
Application of PET/MRI in Gynecologic Malignancies
Ebrahimi, Sheida , Lundström, Elin , Batasin, Summer, Hedlund, Elisabeth, Stålberg, Karin , Ehman, Eric C. , Iranpour, Negaur, Loubrie, Stéphane , Schlein, Alexandra , Rakow‐Penner, Rebecca , Rakow-Penner, Rebecca , Sheth, Vipul R.

Cancers | April 12, 2024 | Volume: 16 | Issue: 8 | Pages: 1478

10.3390/cancers16081478 | PMID 38672560 Get It

The diagnosis, treatment, and management of gynecologic malignancies benefit from both positron emission tomography/computed tomography (PET/CT) and MRI. PET/CT provides important information on the local extent of disease as well as diffuse metastatic involvement. MRI offers soft tissue delineation and loco-regional disease involvement. The combination of these two technologies is key in diagnosis, treatment planning, and evaluating treatment response in gynecological malignancies. This review aims to assess the performance of PET/MRI in gynecologic cancer patients and outlines the technical challenges and clinical advantages of PET/MR systems when specifically applied to gynecologic malignancies.
Routine External Iliac Artery Cannulation in Robotic Cardiac Surgery: Role of the Corona “Vitae” in Distal Limb Perfusion
Kitahara, Hiroto , Johnson, Blaine , Grady, Kaitlin, Balkhy, Husam H. , AlJamal, Yazan N , Johnson, Blaine , Balkhy, Husam H , AlJamal, Yazan

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | April 12, 2024 | Volume: 19 | Issue: 2 | Pages: 192-195

10.1177/15569845241239911 | PMID 38606852 Get It

Objective: Femoral artery cannulation is the most commonly used approach for cardiopulmonary bypass (CPB) in robotic cardiac procedures. However, without adding a distal perfusion cannula, leg ischemia can occur in up to 11.5% of patients. There is a well-described 2 to 4 mm size arterial branch that originates from the medial side of the external iliac artery or inferior epigastric artery, immediately above the inguinal ligament, and connects to the obturator artery. Therefore, it was historically named the corona mortis , which means “crown of death” in Latin. When peripheral cannulation is performed above this branch in the external iliac artery, we consider it a corona “vitae” because of its role as a limb-saving collateral. We report herein our standard technique of peripheral cannulation without the need of a distal perfusion cannula and preventing limb ischemia. Methods: We included all patients who underwent robotic cardiac surgery with peripheral cannulation over a 16-month period at our institution. We cannulated just above the level of the inguinal ligament through a 2 to 3 cm transverse skin incision. The incidence of limb ischemia and vascular complications was recorded and analyzed. Results: During the study period, 133 patients underwent robotic cardiac procedures with peripheral “external iliac” CPB. The size of the cannula was 21F or larger in 73% and 23F in 54% of the patients. No leg ischemia or femoral artery complications requiring additional intervention occurred. Conclusions: External iliac cannulation can be successfully performed in robot-assisted cardiac surgery using relatively large cannulas without the need of a distal limb perfusion catheter, with good results. In our view, given the importance of the corona mortis (“crown of death” in Latin) in perfusing the limb during CPB, we propose a new name for this artery in robotic cardiac surgery, namely, the corona vitae (“crown of life” in Latin).